Related Experiment Videos
Somatostatin receptor scintigraphy in thyroid eye disease
1Department of Endocrinology/Metabolism, Gutenberg-University Hospital, Mainz, Germany.
Summary
Somatostatin receptor imaging using Pentetreotide effectively detects thyroid eye disease (TED) activity. This method shows increased orbital uptake in TED patients and predicts treatment response, aiding in disease evaluation.
Area of Science:
- Nuclear Medicine
- Endocrinology
- Ophthalmology
Background:
- Thyroid eye disease (TED) involves orbital lymphocytic infiltration.
- Activated lymphocytes in TED express somatostatin (SMS) receptors.
- Pentetreotide, a radiolabeled SMS analog, is suitable for receptor imaging.
Purpose of the Study:
- To evaluate the utility of SMS receptor imaging with Pentetreotide for assessing TED.
- To determine if Pentetreotide uptake correlates with disease activity and treatment response.
Main Methods:
- 80 patients with TED underwent SPECT imaging after Pentetreotide injection.
- Semiquantitative analysis of orbital Pentetreotide accumulation was performed.
- Comparison with control subjects and correlation with treatment outcomes were analyzed.
Main Results:
- TED patients exhibited significantly higher orbital Pentetreotide accumulation compared to controls (15 vs. 5 cts/vox/MBq).
- Active TED cases showed even greater uptake (23 cts/vox/MBq), with 90% sensitivity and 100% specificity.
- Pretreatment orbit-to-brain ratio predicted treatment response with 88% positive and 100% negative predictive values.
Conclusions:
- SMS receptor scintigraphy with Pentetreotide is a valuable semiobjective tool for evaluating TED.
- The imaging technique aids in assessing initial disease stages and monitoring treatment response.